ADDvise wins public tender worth 1.8 MSEK + option of 1.8 MSEK

05-12-2016   Non-regulatory press release

The tender covers anesthesia and intensive care supplies. The agreement runs for 2 years with an option of another 2 years. Value on an annual basis is approximately 0.9 MSEK.

Delivery will start on June 1st, 2017.

- Femklövern is one of our major customers. We are pleased and grateful for the continued confidence, says Rikard Akhtarzand, CEO of ADDvise Group.    

For further information, please contact: Rikard Akhtarzand, CEO +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 5th, 2016 at 11:15 CET.  

About ADDvise Group ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise Group’s nomination committee for the Annual General Meeting 2022

Regulatory

In accordance with the resolution at the 2021 annual general meeting of ADDvise Group AB, the nomination committee for the annual general meeting 2022 shall be composed of representatives of the three largest shareholders by votes listed in the shareholders’ register, which is maintained by Euroclear Sweden as of 30 June 2021, and the chairman…

ADDvise Group’s reporting dates 2022

Regulatory

Year-End Report 2021 (Jan-Dec)                                 2022-02-24 Last day for shareholders to request                            2022-03-18 an item to be included to the agenda of the Annual General Meeting Interim Report (Jan-March 2022)                       …

On account of the difference in price movements in ADDvise Group’s shares

Regulatory

ADDvise Group AB (publ) (“ADDvise” and the “Company”) notes positive price movements in the Company's shares. ADDvise's share of series A carries one vote and share of series B carries one tenth of a vote, and besides this difference, the Company is not aware of any information concerning the Company which explains the difference between…

ADDvise updates long-term financial goals

Regulatory

ADDvise Group AB raises its long-term EBITDA financial target from 15% to 20%. ADDvise also raises its long-term revenue growth target from 20% to 25%. Other long-term financial goals remain unchanged. For the financial year 2022, on a pro forma basis rolling 12 months, ADDvise expects to reach revenue of SEK 1 billion with an…